Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients

NCT01322152 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT01322152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01322152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
June 30, 2013
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer